About Arfolitixorin

What is Arfolitixorin?

Arfolitixorin is a new experimental therapy that can potentially improve the effectiveness of standard of care chemotherapy for patients living with metastatic colorectal cancer (mCRC).

Arfolitixorin is being developed by Isofol and is the first major innovation to the first-line mCRC treatment regimen in decades. Arfolitixorin aims to help mCRC patients reduce tumor size and maintain quality of life.

Arfolitixorin is the first pure form of MTHF, an active pharmaceutical ingredient that can improve the effectiveness of standard of care chemotherapy. As the pure form of MTHF, arfolitixorin does not require complicated metabolic steps to become biologically active.

All patients regardless of their ability to perform this complicated drug metabolism are given the same chance.

Arfolitixorin is being studied in a global Phase 3 AGENT Study (ISO‑CC‑007), in the U.S., Canada, Europe, Japan and Australia.